• Corpus ID: 6877371

Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.

  title={Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.},
  author={Yi-Wen Huang and Li‐Shu Wang and Hsiang-lin Chang and Weiping Ye and Michael K. Dowd and Peter Justin Wan and Young C. Lin},
  journal={Anticancer research},
  volume={26 3A},
BACKGROUND Gossypol, a natural compound present in cottonseeds, displays antiproliferative and pro-apoptotic effects against various cancer cells. The (-)-gossypol enantiomer is a more potent inhibitor of cancer cell growth. Here, the molecular mechanisms of apoptosis induced by (-)-gossypol were studied in human prostate cancer cells. MATERIALS AND METHODS After the prostate cancer cell DU-145 had been treated with (-)-gossypol, the trypan blue exclusion assay and DNA fragment end-labeling… 

Figures and Tables from this paper

Induction of apoptosis by (-)-gossypol-enriched cottonseed oil in human breast cancer cells.

The results suggest that the growth inhibitory effect of (-)-GPCSO on MCF-7 and PCHBCEC is due, at least partially, to the induction of cell apoptosis, which is mediated by down-regulation of Bcl-2 expression at both the mRNA and protein levels.

(-)-Gossypol reduces invasiveness in metastatic prostate cancer cells.

Findings illustrated that (-)-gossypol reduced in vitro invasion of both the parental MAT-LyLu cells and the isolated MLL cells, suggesting that (--gOSSypol might serve as a chemotherapeutic and/or chemopreventive agent.

Antitumor activity of gossypol polyphenol is mediated through apoptosis induction and sub-G1 cell cycle arrest in SEG-1 human esophageal cancer cell line.

The main objective of the present study was to evaluate the antitumor effects of gossypol in human esophageal cancer cells (SEG-1) by studying its effects on apoptosis induction and cell cycle phase

Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.

In the PC-3 tumour xenograft study, (-)-gossypol given once a day for 7 days significantly inhibited tumour growth in a dose-dependent manner and it suggested that cell apoptosis and inhibition of angiogenesis might contribute to the anticancer action of (--gOSSypol.

Gossypol inhibits the growth of MAT-LyLu prostate cancer cells by modulation of TGFbeta/Akt signaling.

The inhibitory effects of GP on the proliferation of MAT-LyLu prostate cancer cells are associated with modulation of TGFbeta1 and Akt signaling, which influence the expression of regulatory proteins such as cyclin D1, Cdk4 and phospho-Rb which regulate cell cycle progression of prostate cancer Cells.

Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells.

Gossypol decreased cell viability and down-regulated the expression of a number of genes in human colon cancer cells

Gossypol inhibited cell survival with decreased expression of a number of genes in the colon cancer cells, and showed significant inhibitory effect under high concentration and longtime treatment.

Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor

Gossypol effectively inhibits the repair and redox activity of APE1 through a direct interaction and results in a statistically higher antitumor activity compared with DDP alone in vivo.

Effect of the BH3 Mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma

In vivo results showed that the intraperitoneal administration of AT-101 increased the median survival of C57BL/6 mice intra peritoneally transplanted with #40a cells and reduced the risk of developing tumors and may have important implications for the design of MM therapies by employing AT- 101 as an anticancer agent in combination with standard therapies.



(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.

The results show that the natural polyphenol inhibitor of Bcl-2/Bcl-xL, (-)-gossypol, can radiosensitize prostate cancer in vitro and in vivo without augmenting toxicity.

The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.

The inhibitory effects of (+/-)-GP on the proliferation of human prostate cancer PC3 cells are associated with induction of TGFbeta1, which in turn influences the expression of the cell cycle-regulatory protein, cyclin D1, in prostate cancer cells.

Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis.

Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers.

The antimitochondrial and enzyme-inhibiting properties of gossypol in human carcinoma cell lines of breast, ovarian, pancreatic, and pancreatic origin are studied by comparing the effects of its purified (+)- and (-)-enantiomers.

(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.

The results suggest that (-)-gossypol is a potent and novel therapeutic able to overcome apoptosis resistance by specifically targeting the activity of antiapoptotic Bcl-2 family members.

In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.

Gossypol, given at a dose of 30 mg/kg per day five days a week for four weeks orally via gavage, was found to decrease the mean tumor weight of treated xenografts by more than 50% as compared to untreated xenografteds, suggesting that gossypOL has potential for further study as an agent for the treatment of primary CNS malignancies.

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.

In vitro and in vivo data suggest that these natural products bind and antagonize the antiapoptotic effects of B-cell lymphocyte/leukemia-2 (Bcl-2) family proteins such as Bcl-x(L).